Val Plex 2

Product Description

Val Plex 2 is a cocktail of horseradish peroxidase (HRP) anti-mouse antibody conjugate and alkaline phosphatase (AP) anti-rabbit antibody conjugate intended for use in the detection of mouse IgG and IgM and rabbit IgG primary antibodies on formalin-fixed, paraffin-embedded (FFPE) tissues in an immunohistochemistry (IHC) procedure performed on Biocare Medical’s VALENT® Automated Slide Staining Platform. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls and should be evaluated within the context of the patient’s clinical history and other diagnostic tests by a qualified pathologist.

Val Plex 2 is a cocktail of HRP anti-mouse antibody conjugate and AP antirabbit antibody conjugate suitable for the detection of mouse and rabbit primary antibodies, respectively, as part of an IHC double-stain procedure on the VALENT Automated Slide Staining Platform. Val Plex 2 is intended to be used in combination with Val DAB Chromogen Kit (VLT8008K) to produce a brown stain at the site of mouse primary antibody binding, and Val Fast Red Chromogen Kit (VLT8019K) to produce a red stain at the site of rabbit primary antibody binding. Val Plex 2 is prepared using a proprietary micro-polymer technology that provides a highly sensitive detection system, with minimal background staining. Val Plex 2 does not use biotin nor streptavidin, thus avoiding non-specific staining associated with endogenous biotin. Val Plex 2 is provided ready-to-use and is intended to be applied as defined by the staining protocols on the VALENT Automated Slide Staining Platform.

Specifications

1. Taylor CR, Cote RJ. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. 3rd Ed. Philadelphia: Saunders Elsevier, 2006.
2. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3rd Ed. Philadelphia: Saunders Elsevier, 2010.
3. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition (M29-A4) Wayne, PA 2014.